Revlimid Slows Multiple Myeloma Relapse (CME/CE)

NEW ORLEANS (MedPage Today) -- For patients whose multiple myeloma is in remission after initial therapy, maintenance with the immune modulator lenalidomide (Revlimid) prolongs the time to relapse, a researcher said here.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news